Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K/A

(Amendment No. 1)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Fiscal Year Ended September 30, 2024

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number 001-38174

 

Citius Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its Charter)

 

Nevada		27-3425913
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

11 Commerce Drive, First Floor, Cranford, NJ 07016

(Address of principal executive offices) (Zip Code)

 

[phone]

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		CTXR		The NASDAQ Capital Market

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ☐ Yes ☒ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. ☐ Yes ☒ No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter (March 28, 2024) was approximately $131,670,000 million.

 

Affiliates for the purpose of this item refers to the issuer’s executive officers and directors and/or any persons or firms (excluding those brokerage firms and/or clearing houses and/or depository companies holding issuer’s securities as record holders only for their respective clients’ beneficial interest) owning 10% or more of the issuer’s common stock, both of record and beneficially.

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: 7,727,243 shares as of December 18, 2024, all of one class of common stock, $0.001 par value.

 

DOCUMENTS INCORPORATED BY REFERENCE: Portions of the Company’s Proxy Statement for the Annual Meeting of Stockholders filed in January 2025 are incorporated by reference in Part III of the Original Filing.

 

 

 

 

 

EXPLANATORY NOTE

 

This Amendment No. 1 to Form 10-K (this “Form 10-K/A”) amends the Annual Report on Form 10-K of Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company,” “we,” “us,” and “our,” as applicable), for the year ended September 30, 2024, that we originally filed with the Securities and Exchange Commission (the “SEC”) on December 27, 2024 (the “Original Filing”). We are filing this Form 10-K/A for the sole purpose of including Exhibit 97.1.

 

Pursuant to the rules of the SEC, Part IV, Item 15 (Exhibit Index) has also been amended to contain the currently dated certifications from our principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. The certifications of our principal executive officer and principal financial officer are attached to this Form 10-K/A as Exhibits 31.3 and 31.4, respectively. Because no financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, we have omitted paragraphs 3, 4 and 5 of the certifications filed with this Form 10-K/A. Additionally, we are not including the certifications under Section 906 of the Sarbanes-Oxley Act of 2002, because we are not filing any financial statements with this Form 10-K/A.

 

Except as set forth in this Form 10-K/A, this Form 10-K/A does not amend or otherwise update any other information in the Original Filing. Other than the information specifically amended and restated herein, this Form 10-K/A does not reflect events occurring after December 27, 2024, the date of the Original Filing, or modify or update those disclosures that may have been affected by subsequent events. Accordingly, this Form 10-K/A should be read in conjunction with the Original Filing and with our filings with the SEC after the Original Filing.

 

 

 

Citius Pharmaceuticals, Inc.

 

FORM 10-K/A

September 30, 2024

 

TABLE OF CONTENTS

 

			Page
Item 15.	Exhibits and Financial Statement Schedules		1
	Signatures		5

 

i

 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

  

Exhibit Number		Description of Document		Registrant’s Form		Dated		Exhibit Number		Filed Herewith
2.1+		Agreement and Plan of Merger, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition, and TenX Merger Sub Inc.		8-K		10/24/2023		2.1
3.1		Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc.		8-K		9/18/2014		3.1
3.2		Certificate of Amendment to the Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc., effective September 16, 2016.		8-K		9/21/2016		3.1
3.3		Certificate of Amendment to the Amended and Restated Articles of Incorporation of Citius Pharmaceuticals, Inc., effective June 9, 2017.		8-K		6/8/2017		3.1
3.4		Certificate of Amendment to the Articles of Incorporation of Citius Pharmaceuticals Inc., dated June 21, 2021.		8-K/A		6/22/2021		3.1
3.5		Amended and Restated Bylaws of Citius Pharmaceuticals, Inc.		8-K		2/9/2018		3.1
3.6		Certificate of Change filed with the Secretary of State of Nevada on November 22, 2024.		8-K		11/26/2024		3.1
4.1		Form of Common Stock Purchase Warrant, dated August 13, 2018, as amended August 8, 2023.		10-K		12/29/2023		4.1
4.2		Form of Pre-Funded Common Stock Purchase Warrant, dated August 13, 2018.		8-K		8/13/2018		4.2
4.3		Form of Underwriter’s Common Stock Purchase Warrant, dated August 13, 2018, as amended August 8, 2023.		10-K		12/29/2023		4.3
4.4		Form of Investor Warrant issued April 3, 2019.		8-K		4/03/2019		4.1
4.5		Form of Placement Agent Warrant issued April 3, 2019.		8-K		4/03/2019		4.2
4.6		Form of Common Stock Purchase Warrant issued September 27, 2019.		8-K		9/27/2019		4.1
4.7		Form of Underwriters Common Stock Purchase Warrant issued September 27, 2019.		8-K		9/27/2019		4.3
4.8		Form of Investor Warrant issued on February 19, 2020.		8-K		2/19/2020		4.1
4.9		Form of Placement Agent Warrant issued on February 19, 2020.		8-K		2/19/2020		4.2
4.10		Form of Investor Warrant issued May 18, 2020.		8-K		5/18/2020		4.1
4.11		Form of Placement Agent Warrant issued May 18, 2020.		8-K		5/18/2020		4.2
4.12		Form of Underwriter Warrant issued August 10, 2020.		8-K		8/10/2020		4.1
4.13		Form of Investor Warrant issued January 27, 2021.		8-K		1/27/2021		4.1
4.14		Form of Placement Agent Warrant issued January 27, 2021.		8-K		1/27/2021		4.2

 

1

 

 

Exhibit Number		Description of Document		Registrant’s Form		Dated		Exhibit Number		Filed Herewith
4.15		Form of Registration Rights Agreement, dated January 24, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto.		8-K		1/27/2021		4.3
4.16		Form of Investor Warrant issued February 19, 2021.		8-K		2/19/2021		4.1
4.17		Form of Placement Agent Warrant issued February 19, 2021		8-K		2/19/2021		4.2
4.18		Form of Warrant issued May 8, 2023.		8-K		5/8/2023		4.1
4.19		Form of Placement Agent Warrant issued May 8, 2023.		8-K		5/8/2023		4.2
4.20		Form of Investor Warrant issued April 30, 2024.		8-K		4/30/2024		4.1
4.21		Form of Investor Warrant issued November 18, 2024.		8-K		11/18/2024		4.1
4.22		Description of Common Stock.		10-K		12/27/24		4.22
10.1*		Citius Pharmaceuticals, Inc. 2014 Stock Incentive Plan.		10-Q		8/15/2016		10.1
10.2*		Form of Citius Pharmaceuticals, Inc. 2014 Stock Incentive Plan Nonqualified Stock Option.		10-Q		8/15/2016		10.2
10.3*		Amended and Restated Employment Agreement between Myron Holubiak and Citius Pharmaceuticals, Inc., executed April 12, 2022, effective May 1, 2022.		10-Q		5/12/2022		10.1
10.4		Second Amendment to the Patent and Technology License Agreement between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc., dated March 20, 2017.		10-Q		5/15/2017		10.8
10.5*		Amended and Restated Employment Agreement between Leonard Mazur and Citius Pharmaceuticals, Inc., dated October 19, 2017.		10-K		12/11/2018		10.23
10.6*		Employment Agreement between Jaime Bartushak and Citius Pharmaceuticals, Inc., dated November 27, 2017.		8-K		12/1/2017		10.1
10.7*		Citius Pharmaceuticals, Inc. 2018 Omnibus Stock Incentive Plan		10-Q		2/14/2018		10.2
10.8		Form of Securities Purchase Agreement between Citius Pharmaceuticals, Inc. and the purchasers named therein, dated March 28, 2018.		8-K		3/29/2018		10.1
10.9+		Patent and Technology License Agreement, dated January 2, 2019, between the Board of Regents of the University of Texas System on behalf of the University of Texas M. D. Anderson Cancer Center and Citius Pharmaceuticals, Inc.		10-Q		2/14/2019		10.1
10.10		First Amendment, dated October 15, 2015, to Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc.		10-Q		2/14/2019		10.2
10.11+		Patent and Technology License Agreement, dated May 14, 2014, between Novel Anti-Infective Technologies, LLC and Leonard-Meron Biosciences, Inc.		10-Q		5/12/2023		10.1

 

2

 

 

Exhibit Number		Description of Document		Registrant’s Form		Dated		Exhibit Number		Filed Herewith
10.12		Form of Securities Purchase Agreement, dated April 1, 2019, by and between Citius Pharmaceuticals, Inc. and the purchasers named therein.		8-K		4/03/2019		10.1
10.13*		Citius Pharmaceuticals, Inc. 2020 Omnibus Stock Incentive Plan.		Schedule 14A		12/20/2019		Appendix A
10.14*		Form of Notice of Stock Option Grant and Stock Option Award Agreement.		10-Q		2/13/2020		10.2
10.15		Form of Warrant Exercise Agreement, dated February 14, 2020, by and between Citius Pharmaceuticals, Inc. and the investor signatory thereto.		8-K		2/19/2020		10.1
10.16		Form of Warrant Exercise Agreement, dated February 14, 2020, by and between Citius Pharmaceuticals, Inc. and the investor signatory thereto.		8-K		2/19/2020		10.2
10.17		Form of Securities Purchase Agreement, dated May 14, 2020, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto.		8-K		5/18/2020		10.1
10.18*		Employment Agreement, effective as of July 14, 2020, between Citius Pharmaceuticals, Inc. and Myron Czuczman.		10-Q		8/14/2020		10.3
10.19+		License Agreement, dated October 6, 2020, between NoveCite, Inc. and Novellus Therapeutics, Limited.		10-K		12/16/2020		10.24
10.20		Form of Securities Purchase Agreement, dated January 24, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto.		8-K		1/27/2021		10.1
10.21		Form of Securities Purchase Agreement, dated February 16, 2021, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto.		8-K		2/19/2021		10.1
10.22*		Citius Pharmaceuticals, Inc. 2021 Omnibus Incentive Stock Plan.		Schedule 14A		4/12/2021		Appendix B
10.23*		Form of Notice of Stock Option Grant and Stock Option Award Agreement.		10-K		12/15/2021		10.29
10.24+		Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy’s Laboratories S.A. and Citius Pharmaceuticals, Inc.		10-K		12/15/2021		10.30
10.25+		Amended and Restated License, Development and Commercialization Agreement, dated as of February 26, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A.		10-K		12/15/2021		10.31
10.26+		Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of August 9, 2018, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A.		10-K		12/15/2021		10.32
10.27+		Amendment No. 2 to Amended and Restated License, Development and Commercialization Agreement, dated as of August 31, 2021, between Eisai, Ltd. and Dr. Reddy’s Laboratories S.A.		10-K		12/15/2021		10.33
10.28		Citius Pharmaceuticals, Inc. 2023 Omnibus Stock Incentive Plan.		Schedule 14A		12/22/2022		Annex A
10.29		Form of Securities Purchase Agreement, dated May 3, 2023, by and between Citius Pharmaceuticals, Inc. and the purchasers signatory thereto.		8-K		5/8/2023		10.1
10.30+		Sponsor Support Agreement, dated as of October 23, 2023, by and among 10XYZ Holdings LP, TenX Keane Acquisition, Citius Pharmaceuticals, Inc. and Citius Oncology, Inc.		8-K		10/24/2023		10.1
10.31+		Form of Amended and Restated Registration Rights Agreement.		8-K		10/24/2023		10.2
10.32+		Form of Amended and Restated Shared Services Agreement.		8-K		10/24/2023		10.3
10.33+		Form of Securities Purchase Agreement, dated as of April 25, 2024, by and among Citius Pharmaceuticals, Inc. and the investors signatory thereto.		8-K		4/30/2024		10.1
10.34+		Amended and Restated Shared Services Agreement, dated, August, 12, 2024, between Citius Pharmaceuticals, Inc. and Citius Oncology, Inc.		8-K		8/16/2024		10.1
10.35+		Amended and Restated Registration Rights Agreement, dated as of August 12, 2024, by and between Citius Oncology, Inc. and the signatories thereto.		8-K		8/16/2024		10.2
10.36+		Side Letter Agreement, dated August 12, 2024, by and by and among Citius Pharmaceuticals, Inc., Citius Oncology, Inc., TenX Keane Acquisition and TenX Merger Sub, Inc.		8-K		8/16/2024		10.3
10.37+		Promissory note, dated August 16, 2024, issued to Citius Pharmaceuticals, Inc. by Citius Oncology, Inc.		8-K		8/16/2024		10.4
10.38		Form of Securities Purchase Agreement, dated as of November 15, 2024, by and among Citius Pharmaceuticals, Inc. and the investors signatory thereto.		8-K		11/18/2024		10.1
19.1		Insider Trading Policy.		10-K		12/27/2024		19.1
21		Subsidiaries.		10-K		12/29/2023		21

 

3

 

 

Exhibit Number		Description of Document		Registrant’s Form		Dated		Exhibit Number		Filed Herewith
23.1		Consent of Independent Registered Public Accounting Firm.		10-K		12/27/2024		23.1
31.1		Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a).		10-K		12/27/2024		31.1
31.2		Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).		10-K		12/27/2024		31.2
31.3		Certification of the Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a).		--		--		--		X
31.4		Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).		--		--		--		X
97.1		Compensation Recovery Policy.		--		--		--		X
EX-101.INS		INLINE XBRL INSTANCE DOCUMENT		--		--		--		X
EX-101.SCH		INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT		--		--		--		X
EX-101.CAL		INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE		--		--		--		X
EX-101.DEF		INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE		--		--		--		X
EX-101.LAB		INLINE XBRL TAXONOMY EXTENSION LABELS LINKBASE		--		--		--		X
EX-101.PRE		INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE		--		--		--		X
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).		--		--		--		X

 

+

Portions of this exhibit have been omitted pursuant to Item 601(b)10 of Regulation S-K or certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2) or 601(a)(5), as applicable. Citius Pharma agrees to furnish supplementally an unredacted copy such exhibit, including any omitted exhibits and schedules, to the SEC upon its request.

*

Management contract or compensatory plan.

 

4

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	CITIUS PHARMACEUTICALS, INC.
Date: January 27, 2025	By:	/s/ Leonard Mazur
		Leonard Mazur
		Chief Executive Officer (Principal Executive Officer)

 

5

Exhibit 31.3

 

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Leonard Mazur, certify that:

 

1.	I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of Citius Pharmaceuticals, Inc.; and

 

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

Date: January 27, 2025	By:	/s/ Leonard Mazur
		Leonard Mazur
		Chief Executive Officer and Chairman
		(Principal Executive Officer)

Exhibit 31.4

 

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jaime Bartushak, certify that:

 

1.	I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of Citius Pharmaceuticals, Inc.; and

 

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

 

January 27, 2025	By:	/s/ Jaime Bartushak
		Jaime Bartushak
		Chief Financial Officer
		(Principal Financial Officer and
		Principal Accounting Officer)

Exhibit 97.1

 

CITIUS PHARMACEUTICALS, INC.

 

COMPENSATION RECOVERY POLICY

 

Adopted by the Board of Directors on November 20, 2023.

 

Introduction

 

The Board of Directors (the “Board”) of Citius Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this policy which provides for the recoupment of certain executive compensation (“Erroneously Awarded Compensation”) in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under the federal securities laws (the “Policy”). This Policy is designed to comply with Section 10D of the Securities Exchange Act of 1934 (the “Exchange Act”) and the rules of the NASDAQ Stock Market.

 

Administration

 

This Policy shall be administered by the Board or, if so designated by the Board, the Compensation Committee, in which case references herein to the Board shall be deemed references to the Compensation Committee. Any determinations made by the Board shall be final and binding on all affected individuals.

 

Covered Executives

 

This Policy applies to the Company’s current and former executive officers, as determined by the Board in accordance with Section 10D of the Exchange Act and the rules of the NASDAQ Stock Market, and such other employees who may from time to time be deemed subject to the Policy by the Board (“Covered Executives”).

 

Recoupment; Accounting Restatement

 

In the event the Company is required to prepare an accounting restatement of its financial statements due to the Company’s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period, the Board will require reasonably prompt reimbursement or forfeiture of any excess Incentive Compensation (as defined below) received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare an accounting restatement.

 

Incentive Compensation

 

For purposes of this Policy, “Incentive Compensation” means any of the following; provided that such compensation is granted, earned, or vested based wholly or in part on the attainment of a financial reporting measure:

 

●

Annual bonuses and other short- and long-term cash incentives.

 

●

Incentive stock options.

 

●

Nonstatutory stock options.

 

●

Stock appreciation rights.

 

 

 

●

Dividend equivalent rights.

 

●

Restricted stock awards.

 

●

Restricted stock unit awards.

 

Financial reporting measures include:

 

●

Company stock price.

 

●

Total shareholder return.

 

●

Revenues.

 

●

Net income.

 

●

Earnings measures such as earnings per share.

 

●

Book value per share.

 

●

Pre-provision net revenue.

 

This Policy applies to all Incentive Compensation received by a Covered Executive (a) after beginning service as a Covered Executive; (b) who served as a Covered Executive at any time during the performance period for the Incentive Compensation; (c) while the Company has a class of securities listed on a national securities exchange or a national securities association; and (d) during the three completed fiscal years immediately preceding the date that the Company is required to prepare an accounting restatement as described above. This Policy shall also apply to any transition period that results from a change in the Company’s fiscal year within or immediately following those three completed fiscal years, provided, however, that a transition period between the last day of the Company’s previous fiscal year and the first day of its new fiscal year that comprises a period of nine to 12 months shall be deemed a completed fiscal year. The Company’s obligation to recover Erroneously Awarded Compensation is not dependent on if or when the restated financial statements are filed with the Securities and Exchange Commission.

 

Excess Incentive Compensation: Amount Subject to Recovery

 

The Erroneously Awarded Compensation will be the amount of Incentive Compensation paid to the Covered Executive that exceeds the amount of Incentive Compensation that otherwise would have been received had it been determined based on the restated amounts, as determined by the Board in accordance with Rule 10D-1 of the Exchange Act and the rules of the NASDAQ Stock Market. Such amount must be computed without regard to any taxes paid.

 

Where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from information in an accounting restatement because the Incentive Compensation was based on stock price or shareholder return, the Board will determine the amount of Erroneously Awarded Compensation based on a reasonable estimate of the effect of the accounting restatement on the stock price or total shareholder return upon which the Incentive Compensation was paid and maintain documentation of the determination of that reasonable estimate and provide such documentation to NASDAQ.

 

For purposes of determining the relevant recovery period, the date that the Company is required to prepare an accounting restatement is the earlier to occur of (a) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an accounting restatement; or (b) the date a court, regulator, or other legally authorized body directs the Company to prepare an accounting restatement.

 

Method of Recoupment

 

The Board will determine, in its sole discretion, the method for recouping Incentive Compensation hereunder, which may include, without limitation:

 

(a) requiring reimbursement of cash Incentive Compensation previously paid;

 

(b) seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;

 

(c) cancelling outstanding vested or unvested equity awards; and/or

 

(d) taking any other remedial and recovery action permitted by law, as determined by the Board.

 

2

 

 

No Indemnification

 

The Company shall not indemnify any Covered Executives against the loss of any incorrectly awarded Incentive Compensation.

 

Interpretation

 

The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the Securities and Exchange Commission or the rules of the NASDAQ Stock Market.

 

Effective Date

 

This Policy shall be effective as of the date it is adopted by the Board (the “Effective Date”) and shall apply to Incentive Compensation that is approved, awarded or granted to Covered Executives on or after that date.

 

Amendment; Termination

 

The Board may amend this Policy from time to time in its discretion and may terminate this Policy at any time.

 

Other Recoupment Rights

 

The Board intends that this Policy will be applied to the fullest extent of the law. The Board may require that any employment agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.

 

Impracticability

 

The Board shall recover Erroneously Awarded Compensation in accordance with this Policy unless such recovery would be impracticable, as determined by the Board in accordance with Rule 10D-1 of the Exchange Act and the rules of the NASDAQ Stock Market. Instances in which recovery may be impracticable include:

 

(a)

after the Company has made a reasonable attempt to recover Erroneously Awarded Compensation, the Board determines that the direct expense paid to a third party to assist in enforcing the policy would exceed the amount to be recovered;

 

(b)

recovery would violate home country law where that law was adopted prior to November 28, 2022, and the Board has obtained an opinion of home country counsel, acceptable to NASDAQ, that recovery would result in such a violation, and must provide such opinion to NASDAQ; or

 

(c)

recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the registrant, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.

 

Successors

 

This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.

 

 

3

 

 

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2024	Dec. 18, 2024	Mar. 28, 2024
Document Information Line Items
Entity Central Index Key	0001506251
Document Type	10-K/A
Document Annual Report	true
Current Fiscal Year End Date	--09-30
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Transition Report	false
Entity File Number	001-38174
Entity Registrant Name	Citius Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	27-3425913
Entity Address, Address Line One	11 Commerce Drive
Entity Address, Address Line Two	First Floor
Entity Address, City or Town	Cranford
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07016
City Area Code	(908)
Local Phone Number	967-6677
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	CTXR
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 131,670,000
Entity Common Stock, Shares Outstanding		7,727,243
Amendment Description	This Amendment No. 1 to Form 10-K (this “Form 10-K/A”) amends the Annual Report on Form 10-K of Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company,” “we,” “us,” and “our,” as applicable), for the year ended September 30, 2024, that we originally filed with the Securities and Exchange Commission (the “SEC”) on December 27, 2024 (the “Original Filing”). We are filing this Form 10-K/A for the sole purpose of including Exhibit 97.1.Pursuant to the rules of the SEC, Part IV, Item 15 (Exhibit Index) has also been amended to contain the currently dated certifications from our principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. The certifications of our principal executive officer and principal financial officer are attached to this Form 10-K/A as Exhibits 31.3 and 31.4, respectively. Because no financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, we have omitted paragraphs 3, 4 and 5 of the certifications filed with this Form 10-K/A. Additionally, we are not including the certifications under Section 906 of the Sarbanes-Oxley Act of 2002, because we are not filing any financial statements with this Form 10-K/A.Except as set forth in this Form 10-K/A, this Form 10-K/A does not amend or otherwise update any other information in the Original Filing. Other than the information specifically amended and restated herein, this Form 10-K/A does not reflect events occurring after December 27, 2024, the date of the Original Filing, or modify or update those disclosures that may have been affected by subsequent events. Accordingly, this Form 10-K/A should be read in conjunction with the Original Filing and with our filings with the SEC after the Original Filing.
Amendment Flag	true
Document Fiscal Period Focus	FY

---